Adaptimmune Therapeutics (NASDAQ:ADAP) – Research analysts at SunTrust Banks cut their Q2 2018 earnings per share estimates for Adaptimmune Therapeutics in a research report issued to clients and investors on Wednesday, May 9th. SunTrust Banks analyst P. Lawson now expects that the biotechnology company will earn ($0.30) per share for the quarter, down from their prior forecast of ($0.27). SunTrust Banks currently has a “Buy” rating and a $18.00 target price on the stock. SunTrust Banks also issued estimates for Adaptimmune Therapeutics’ Q4 2018 earnings at ($0.34) EPS, FY2018 earnings at ($0.57) EPS, FY2019 earnings at ($1.30) EPS, FY2020 earnings at ($1.24) EPS, FY2021 earnings at ($0.62) EPS and FY2022 earnings at ($0.13) EPS.
Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). The business had revenue of $4.27 million during the quarter, compared to the consensus estimate of $9.38 million. Adaptimmune Therapeutics had a negative return on equity of 32.57% and a negative net margin of 160.83%.
Other equities analysts have also issued research reports about the company. BidaskClub lowered Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday. Leerink Swann reaffirmed an “outperform” rating on shares of Adaptimmune Therapeutics in a research note on Thursday, March 15th. Raymond James set a $20.00 price objective on Adaptimmune Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, May 9th. ValuEngine raised Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Finally, Cowen reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Wednesday, May 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. Adaptimmune Therapeutics currently has a consensus rating of “Hold” and an average target price of $15.69.
NASDAQ ADAP opened at $12.77 on Monday. The stock has a market capitalization of $1.23 billion, a PE ratio of -15.96 and a beta of 1.17. Adaptimmune Therapeutics has a twelve month low of $12.57 and a twelve month high of $13.52.
In other news, major shareholder Enterprise Associates 14 New bought 1,268,508 shares of the firm’s stock in a transaction that occurred on Friday, March 23rd. The shares were bought at an average cost of $1.91 per share, for a total transaction of $2,422,850.28. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Orbimed Advisors Llc sold 1,048,067 shares of the business’s stock in a transaction dated Thursday, March 29th. The stock was sold at an average price of $11.50, for a total value of $12,052,770.50. The disclosure for this sale can be found here. In the last ninety days, insiders bought 9,385,254 shares of company stock valued at $17,966,655. Corporate insiders own 24.45% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Raymond James & Associates purchased a new stake in shares of Adaptimmune Therapeutics in the fourth quarter worth about $114,000. SG Americas Securities LLC purchased a new stake in shares of Adaptimmune Therapeutics in the first quarter worth about $239,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of Adaptimmune Therapeutics in the first quarter worth about $257,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Adaptimmune Therapeutics in the fourth quarter worth about $244,000. Finally, California Public Employees Retirement System purchased a new stake in shares of Adaptimmune Therapeutics in the fourth quarter worth about $287,000. Institutional investors own 55.78% of the company’s stock.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.